Blistering dissent of the prevailing notion in the US that we need more drug approvals without good data!https://t.co/hlgZ1gdU6T
— V Prasad (@VinayPrasad82) August 16, 2016
Strong editorial from Vanderbilt's Craig Lindsley (former Merck) on death of basic science. cc: @Dereklowe https://t.co/9u28zasKMK
— Lisa Jarvis (@lisamjarvis) August 18, 2016
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges https://t.co/mzisV2owk6 pic.twitter.com/VS8vAoBS6d
— Biotech Radar (@BiotechRadar) August 9, 2016
Original Article: Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat https://t.co/1cVV31da2L pic.twitter.com/EeebXs99bm
— NEJM (@NEJM) August 10, 2016
The FDA, Juno Therapeutics, and the ethical imperative of transparency ?https://t.co/rVw0PP8zGG
— Arsalan Arif (@AKAarsalan) August 15, 2016
Fascinating @NEJM study about acquired resistance to anti-PD1 rx: somatic LOF mutations in interferon genes https://t.co/KV0z7Genul
— Robert Plenge (@rplenge) July 14, 2016
Amazing initial data for Rhythm's MC4R agonist Setmelanotide in POMC Deficiency #Obesityhttps://t.co/1CJbvrIdG5 pic.twitter.com/IQ4M7Mmf6v
— Andy Biotech (@AndyBiotech) July 21, 2016
Open Access: What are the next gen most promising drugs in #myeloma? Fantastic Review #BCJ https://t.co/oivdr0lebI @mtmdphd @DrAnasYounes
— Vincent Rajkumar (@VincentRK) July 29, 2016
STM Perspective by @rplenge
— Andy Biotech (@AndyBiotech) July 28, 2016
Disciplined approach to drug discovery and early developmenthttps://t.co/qx8HMZHdvA pic.twitter.com/MSgVhiiIQc
FDA commish Califf pens editorial in Journal of the ACC on the future of cardiovascular medicine: https://t.co/90PyJap16W
— Zach Brennan (@ZacharyBrennan) August 9, 2016
Improving clinical trial enrollment with behavioral economicshttps://t.co/S42NFGrNsB
— Andy Biotech (@AndyBiotech) July 22, 2016
WSJ https://t.co/EQJamETzHU pic.twitter.com/1vn3qBs0pv
RSS Feed
